Commissioners report Lucentis pressure from Newcastle FT

FINANCE: North Tyneside PCT, Northumberland CT and Newcastle PCT are facing overspending risks in relation to Newcastle upon Tyne Hospitals Foundation Trust, largely attributable to use of Lucentis (ranibizumab injection).

You need to be signed in to read more


Subscribe for unlimited access

With a HSJ subscription you’ll unlock:

  • All of and our HSJ mobile app
  • News and insight on all areas of public funded healthcare
  • Expert commentary, insight and analysis from industry leaders
  • 9 weekly ‘Expert Briefing’ insight emails covering a variety of specialist topics

Sign into your account here